Datroway Approved in EU for Metastatic TNBC as First TROP2-Directed Therapy
Datroway has been approved in the EU as the only TROP2-directed therapy demonstrating overall survival benefit for first-line treatment in metastatic TNBC patients not eligible for immunotherapy.